Epitope sales and marketing update

EPT's loss widened to $14.7 million ($1.67 per share) on revenues of $3.3 million in the 1993 fiscal year ended Sept. 30. In 1992 the loss was $7.8 million (90 cents) on revenues of $3 million.

Sales of EPiblot AIDS confirmatory test rose 10 percent while OraSure oral specimen collection device sales fell 15 percent. ...